This is a Phase 4, non-interventional, observational study to collect detailed data on the clinical characteristics, clinical outcomes and medical management of ISM in real-world settings. The study will describe the demographic and clinical characteristics of ISM participants, including anaphylaxis and bone manifestations in ISM. Quality of life and disease control will be assessed through participant questionnaires. The study will also evaluate real world ISM treatment management, including use of avapritinib.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Baseline Demographics
Timeframe: Baseline (Month 1)
Change From Baseline in Patient-Reported Outcomes Scores
Timeframe: Baseline up to Month 61
Change From Baseline in Serum KIT D816V Variant Allele Frequency (VAF)
Timeframe: Baseline up to Month 61
Change From Baseline in Serum Tryptase
Timeframe: Baseline up to Month 61
Change From Baseline in Indolent Systemic Mastocytosis (ISM) Symptom-Directed Therapies
Timeframe: Baseline up to Month 61